COST-EFFECTIVENESS OF GLATIRAMER ACETATE AND INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS, BASED ON THE COMBIRX STUDY

被引：0
|
作者：
Darba, J. [1 ]
Kaskens, L. [2 ]
Sanchez-de la Rosa, R. [3 ]
机构：
[1] Univ Barcelona, Barcelona, Spain
[2] BCN Hlth, Barcelona, Spain
[3] TEVA Pharma, Madrid, Spain
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.1827
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
下载
收藏
页码：A623 / A623
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States
    Hernandez, Luis
    Guo, Shien
    Kinter, Elizabeth
    Fay, Monica
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (07) : 684 - 695
  • [2] Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis
    Kalincik, Tomas
    Jokubaitis, Vilija
    Izquierdo, Guillermo
    Duquette, Pierre
    Girard, Marc
    Grammond, Pierre
    Lugaresi, Alessandra
    Oreja-Guevara, Celia
    Bergamaschi, Roberto
    Hupperts, Raymond
    Grand'Maison, Francois
    Pucci, Eugenio
    Van Pesch, Vincent
    Boz, Cavit
    Iuliano, Gerardo
    Fernandez-Bolanos, Ricardo
    Flechter, Shlomo
    Spitaleri, Daniele
    Cristiano, Edgardo
    Verheul, Freek
    Lechner-Scott, Jeannette
    Amato, Maria Pia
    Antonio Cabrera-Gomez, Jose
    Saladino, Maria Laura
    Slee, Mark
    Moore, Fraser
    Gray, Orla
    Paine, Mark
    Barnett, Michael
    Havrdova, Eva
    Horakova, Dana
    Spelman, Timothy
    Trojano, Maria
    Butzkueven, Helmut
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (09) : 1159 - 1171
  • [3] Interferon beta-1a in relapsing-remitting multiple sclerosis
    Blumhardt, L
    HOSPITAL MEDICINE, 1999, 60 (03): : 192 - 195
  • [4] Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis
    Stephanie R. Earnshaw
    Jonathan Graham
    MerriKay Oleen-Burkey
    Jane Castelli-Haley
    Kenneth Johnson
    Applied Health Economics and Health Policy, 2009, 7 (2) : 91 - 108
  • [5] Cost Effectiveness of Glatiramer Acetate and Natalizumab in Relapsing-Remitting Multiple Sclerosis
    Earnshaw, Stephanie
    Graham, Jonathan
    Oleen-Burkey, MerriKay
    Castelli-Haley, Jane
    Johnson, Kenneth
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2009, 7 (02) : 91 - 108
  • [6] COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF SUBCUTANEOUS INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Espallardo, O.
    Crespo, C.
    Polanco, C.
    Nieves, D.
    VALUE IN HEALTH, 2009, 12 (07) : A366 - A367
  • [7] COST-EFFECTIVENESS OF FINGOLIMOD, TERIFLUNOMIDE, DIMETHYL FUMARATE AND INTRAMUSCULAR INTERFERON BETA-1A IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Zhang, X.
    Hay, J. W.
    VALUE IN HEALTH, 2014, 17 (03) : A59 - A60
  • [8] Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis
    Oreja-Guevara, C.
    Bermejo, P. E.
    Miralles, A.
    Gabaldon, L.
    Aguilar, M. J.
    Diez-Tejedor, E.
    NEUROLOGIA, 2009, 24 (07): : 435 - 438
  • [9] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON BETA-1A IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SCOTLAND
    Hernandez, L.
    Guo, S.
    Toro-Diaz, H.
    Carroll, S.
    Farooq, Syed S. F.
    VALUE IN HEALTH, 2015, 18 (07) : A756 - A756
  • [10] COST-EFFECTIVENESS OF DACLIZUMAB VERSUS INTERFERON BETA-1A IN THE TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATES
    Rao, D.
    Heidari, E.
    Kamal, K. M.
    Dashputre, A. A.
    VALUE IN HEALTH, 2018, 21 : S206 - S206
12345